Published in Cancer on June 25, 2003
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol (2009) 2.31
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Ultrasound guidance versus the landmark technique for the placement of central venous catheters in the emergency department. Acad Emerg Med (2002) 2.21
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol (2004) 2.17
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther (2005) 1.83
Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol (2010) 1.83
Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol (2003) 1.82
Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther (2004) 1.74
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res (2006) 1.72
cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ Res (2002) 1.71
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A (2006) 1.61
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int (2010) 1.61
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol (2011) 1.59
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol (2004) 1.53
Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol (2007) 1.52
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol (2007) 1.52
Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol (2002) 1.50
HMGA2 participates in transformation in human lung cancer. Mol Cancer Res (2008) 1.44
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol (2009) 1.43
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Int J Cancer (2003) 1.43
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res (2007) 1.42
Association of clinical and laboratory variables with ultrasound findings in right upper quadrant abdominal pain. South Med J (2005) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
Subcutaneous phaeohyphomycosis caused by Cladophialophora bantiana. Arch Pathol Lab Med (2005) 1.40
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer (2008) 1.39
New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol (2008) 1.39
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol (2002) 1.39
Transitional cell ovarian carcinoma in a BRCA1 mutation carrier. Obstet Gynecol (2002) 1.39
Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol (2004) 1.37
Inflammatory responses to pneumovirus infection in IFN-alpha beta R gene-deleted mice. J Immunol (2005) 1.34
Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. J Allergy Clin Immunol (2009) 1.34
Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol (2003) 1.33
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res (2004) 1.32
Translation of the National Institutes of Health Diabetes Prevention Program in African American churches. J Natl Med Assoc (2011) 1.31
Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res (2005) 1.31
Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer (2004) 1.30
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate (2007) 1.29
Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol (2004) 1.24
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst (2009) 1.21
Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res (2003) 1.18
Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol (2007) 1.18
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int (2010) 1.15
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol (2010) 1.15
Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res (2008) 1.11
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol (2007) 1.10
Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer (2007) 1.09
Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res (2006) 1.08
Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo. BMC Immunol (2009) 1.06
Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol (2002) 1.05
CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol (2005) 1.04
Health literacy, health information seeking behaviors and internet use among patients attending a private and public clinic in the same geographic area. J Community Health (2014) 1.03
Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol (2006) 1.01
Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol (2007) 1.01
Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples. Cancer (2002) 1.01
Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem (2004) 1.00
Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res (2007) 0.99
cGMP-dependent protein kinase II modulates mPer1 and mPer2 gene induction and influences phase shifts of the circadian clock. Curr Biol (2003) 0.99
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol (2005) 0.99
Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol (2002) 0.99
Breast masses in males: multi-institutional experience on fine-needle aspiration. Diagn Cytopathol (2002) 0.98
Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol (2009) 0.98
Eosinophils from lineage-ablated Delta dblGATA bone marrow progenitors: the dblGATA enhancer in the promoter of GATA-1 is not essential for differentiation ex vivo. J Immunol (2007) 0.98
Microsatellite instability among individuals of Hispanic origin with colorectal cancer. Cancer (2010) 0.98
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res (2009) 0.97
Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res (2003) 0.96
It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL. J Acquir Immune Defic Syndr (2004) 0.96
Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 0.95
Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev (2006) 0.95
p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int (2009) 0.94
Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol (2007) 0.94
Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol (2009) 0.94
False-positive sentinel lymph nodes in breast cancer patients caused by benign glandular inclusions: report of three cases and review of the literature. Am J Clin Pathol (2008) 0.93
Abnormal neocortical development in mice lacking cGMP-dependent protein kinase I. Brain Res Dev Brain Res (2005) 0.93
Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol (2009) 0.93
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology (2007) 0.92
Current preferences for breast reduction techniques: a survey of board-certified plastic surgeons 2002. Plast Reconstr Surg (2004) 0.92
Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol (2002) 0.91
A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. Hepatology (2006) 0.91
Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett (2005) 0.91
Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2009) 0.90
Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol (2003) 0.90
MKK4 status predicts survival after resection of gastric adenocarcinoma. Arch Surg (2006) 0.90
Molecular profiling of individual tumor cells by hyperspectral microscopic imaging. Transl Res (2011) 0.90
Selective identification of secreted and transmembrane breast cancer markers using Escherichia coli ampicillin secretion trap. Cancer Res (2005) 0.89
Differential roles of telomere attrition in type I and II endometrial carcinogenesis. Am J Pathol (2008) 0.89
Viable mice with compound mutations in the Wnt/Dvl pathway antagonists nkd1 and nkd2. Mol Cell Biol (2007) 0.89
A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment. Am J Clin Pathol (2005) 0.89
Patient and duct selection for nipple duct lavage. Am J Surg (2004) 0.88
ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer (2002) 0.87